Global Preventive Asthma Drugs Market to grow at a CAGR of 5.20% by 2019

About asthma

According to the Global Initiative for Asthma, asthma is a chronic disease, which is characterized by wheezing, shortness of breath, chest tightness, and cough over a period of time. The symptoms worsen due to the increased secretion of mucus, bronchoconstriction, and thickening of the walls of the airways, resulting in difficulty in expiration. According to the American Academy of Allergy, Asthma, and Immunology, asthma is classified into four types: exercise-induced, allergic, occupational, and childhood. Also, asthma can be classified into two categories: allergic and non-allergic, as per the classification of Asthma and Allergy Foundation of America. Asthma can be managed by preventive medications, which should be administered to the patient regularly to improve his quality of life by controlling the exacerbations.

Technavio's analysts forecast the global preventive asthma drugs market to grow at a CAGR of 5.20% over the period 2014-2019.

Covered in this report

This report covers the present scenario and the growth prospects of the global preventive asthma drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sale of the following classes of drugs used to treat asthma:

Immunosuppressants
Leukotriene antagonists
Mast cell stabilizers
Corticosteroids
Combination of LABA/ ICS

This report includes a discussion of the market in the following three regions:
Americas: The major countries focused in the Americas are the US, Canada, Mexico, and Brazil
EMEA: The major countries in this region are the UK, Germany, Italy, France, Spain and Middle Eastern and African countries such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
APAC: The major countries in this region are Japan, China, Australia, Singapore, South Korea, and India

Technavio's report, Global Preventive Asthma Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape of the global preventive asthma drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Download Sample Copy of Report at http://www.marketresearchreports.biz/sample/sample/404944

Key regions
Americas
APAC
EMEA

Key vendors
AstraZeneca
F. Hoffmann-La Roche
GlaxoSmithKline
Merck
Novartis

Other prominent vendors
Abbott
Amgen
AptarGroup
Biotest
Boehringer Ingelheim
Chiesi Farmaceutici
Cytos
Dainippon Sumitomo
Medicinova
Mylan
Novartis
Orchid Chemicals and Pharmaceuticals
Pfizer
Rottapharm Madaus
Skyepharma
Sosei
Sunovion
Teva Pharmaceutical
Theravance
Vectura

Key market driver
High prevalence of asthma
For a full, detailed list, view our report

Key market challenge
Unknown disease etiology
For a full, detailed list, view our report

Key market trend
Growing popularity of combination therapies
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2019 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

State Tower
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
Email: sales@marketresearchreports.biz

This release was published on openPR.